Skip to content

Microdosing: all studies

Page 43 of 56: studies 421 to 430 of 555, newest first. Back to the microdosing overview

Research

Addressing blinding in classic psychedelic studies with innovative active placebos.

The International Journal of Neuropsychopharmacology April 1, 2025 Jacob S. Aday, Otto Simonsson, Emmanuelle A. D. Schindler et al. 25 citations

Classic psychedelics have shown promise in the treatment of various neuropsychiatric disorders. However, weak blinding integrity has been argued to limit the interpretability of therapeutic effects observed in psychedelic clinical trials, highlighting the need to explore alternative active placebos. Here, we aimed to describe the drawbacks of current placebo conditions used in classic...

DOI: 10.1093/ijnp/pyaf023 (opens in new tab) Full text (opens in new tab) Psychedelic research Clinical trials methodology Placebo effect Pharmaceutical testing +1

Psilocybin Dispensaries and Online Health Claims in Canada

JAMA Network Open April 1, 2025 Jenna Matsukubo, Sarah Dickson, Jennifer Xiao et al. 7 citations

Importance There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there have been anecdotal reports of increasing access via unregulated online purchases and retail dispensaries. Objective To describe access to and the characteristics of psilocybin dispensaries across Canada and the health claims and warnings made on...

DOI: 10.1001/jamanetworkopen.2025.2853 (opens in new tab) Psilocybin Dispensary Advertising Product mathematics +1

Do undergraduates’ views of psychedelics relate to the context for psychedelic use?

Drug Science, Policy and Law March 1, 2025 Dan Petrovitch, Jason van Allen, Sean M. Mitchell et al. 1 citation

Psychedelic drug policy is changing, both in the USA and internationally. However, psychedelic use is not homogeneous, as there are multiple unique contexts for use, including clinical therapies, naturalistic use, and microdosing. There are notable differences between these contexts regarding emerging evidence for safety, therapeutic efficacy, likely future legality, and more. We compared...

The Use of Psychedelics in Chronic Pain – A Scoping Review

RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia February 7, 2025 Hugo Santos, Catarina Redinha, Catarina Pereira et al.

Introdução: A dor crónica é uma condição complexa que afeta uma parte significativa da população mundial. As abordagens terapêuticas atuais muitas vezes não são suficientes, o que leva à exploração de novas opções, como os psicadélicos. Objetivos: Mapear e compilar a literatura sobre o uso dos psicadélicos no tratamento da dor crónica, detalhando as características dos estudos, as populações...

DETERMINATION OF TRYPTAMINE ALKALOIDS AND THEIR STABILITY IN PSYCHOTROPIC MUSHROOMS

The International Journal of Neuropsychopharmacology February 1, 2025 Martin Kuchař, Klara Gotwaldova, Jan Borovička et al. 1 citation

Abstract Synthetic psilocybin (PSB), but also the PSB-containing mushrooms are used for psychedelic therapy and microdosing. It is necessary to know alkaloids variability and stability in wild-grown mushrooms. Concentrations of other psychotropic (or potentially psychotropic) tryptamines such as psilocin (PS), baeocystin (BA), norbaeocystin (NB), and aeruginascin (AE) are also relevant. This...

ANXIOLYTIC- AND PROCOGNITIVE-LIKE EFFECTS OF A 30-DAY CHRONIC TREATMENT WITH A LOW NON-PSYCHEDELIC DOSE OF PSILOCYBIN IN C57BL/6J MICE

The International Journal of Neuropsychopharmacology February 1, 2025 Sofia Nasini, Sara Tidei, Benedetta Barzon et al.

Abstract Background For centuries, American indigenous populations have utilized psilocybin-containing mushrooms for both traditional medical and religious purposes, often in the context of psychedelic experiences. More recently, there has been a notable increase in the interest for and in the practice of psilocybin 'microdosing': regular intake of psilocybin-containing mushrooms in amounts...

EFFECT OF ACUTE PSILOCYBIN ON THERMAL AND NEUROPATHIC PAIN IN RODENTS

The International Journal of Neuropsychopharmacology February 1, 2025 Martha López-canul, Vivienne Nguyen, Antonio Inserra et al.

Abstract Background Pain is a major health problem resulting in a high degree of suffering, physical, psychological and social impairments, and exorbitant health care costs1-2. Effective pain treatments are limited and are often accompanied by significant side effects3. Preclinical and clinical studies suggest that psychedelics, specifically psilocybin, can reset brain areas of functional...

DOI: 10.1093/ijnp/pyae059.091 (opens in new tab) Psilocybin Neuropathic pain Hallucinogen Acute pain +2

Cardiovascular effects and safety of classic psychedelics.

Nature cardiovascular research February 1, 2025 Acile Nahlawi, Leon M Ptaszek, Jeremy N Ruskin 15 citations

Psychedelics, used for millennia in spiritual and healing practices, have emerged as promising treatments for mental health conditions including depression, post-traumatic stress disorder (PTSD), substance use disorders and anxiety. Despite the therapeutic potential of psychedelics and their increasing use in both medical and nonmedical settings, there is a paucity of data on their...

Psychedelics and schizophrenia: a double-edged sword.

Molecular Psychiatry February 1, 2025 Jacopo Sapienza, Francesca Martini, Stefano Comai et al. 11 citations

Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experiments on patients with schizophrenia have been conducted up to date, except for some old semi-anecdotal studies mainly performed in the time-span '50s-'60s. Notably, these studies reported interesting findings, particularly on the improvement of...

DOI: 10.1038/s41380-024-02743-x (opens in new tab) Full text (opens in new tab) Schizophrenia treatment Mental health research Psychedelics Psychiatric medicine

Ketamine-Assisted Psychotherapy for Antisocial Personality Disorder: A Case Report.

Journal of Psychoactive Drugs January 7, 2025 Matthew Hicks, Heather Zwickey, Ryan Bradley 2 citations

There are currently no evidence-based treatment guidelines for antisocial personality disorder (ASPD). Instead, treatment typically focuses on comorbid conditions. There is currently no literature documenting cases or research, theoretical or otherwise of using ketamine-assisted therapy or any other psychedelic therapy in cases of ASPD. In this case report, a 43-year-old man seeking...

DOI: 10.1080/02791072.2025.2449911 (opens in new tab) Full text (opens in new tab) Antisocial personality disorder Case report Ketamine-assisted psychotherapy Mental health treatment +2